Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board

Tel Aviv, Israel/Vancouver, Canada, July 11, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Dr. Fatima Cody Stanford, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, to its Scientific Advisory Board. Dr. Stanford brings extensive expertise in the treatment of obesity, making her a valuable addition to Clearmind's mission of transforming the treatment landscape for obesity by advancing MEAI as a potential treatment.

Dr. Stanford is currently associated with Massachusetts General Hospital and is an Associate Professor of Medicine and Pediatrics at Harvard Medical School, where she serves as an educator, researcher, and policy maker. Her extensive academic background includes a Bachelor of Science and Master of Public Health from Emory University, a MD from the Medical College of Georgia School of Medicine, a Masters of Public Administration from the Harvard Kennedy School of Government and a MBA from the Quantic School of Business and Technology. Dr. Stanford completed her Obesity Medicine & Nutrition Fellowship at Massachusetts General Hospital and Harvard Medical School, further enhancing her expertise in the field.

With a career dedicated to bridging the gaps between medicine, public health, and policy, Dr. Stanford has become a sought-after expert in obesity medicine, both nationally and internationally. Her unique perspective and multidisciplinary approach are aligned with Clearmind Medicine's vision to develop innovative treatments for addiction and address the underlying causes, including obesity.

"We are delighted to welcome Dr. Fatima Cody Stanford to our Scientific Advisory Board. Her diverse experience, combined with Clearmind's commitment to advancing psychedelic-based therapies, holds great promise for individuals struggling with metabolic syndrome and obesity. We look forward to leveraging her expertise as we continue to develop innovative treatments that address obesity, which is considered by many to be a true epidemic of the 21st century." said Clearmind’s Chief Executive Officer, Dr. Adi Zuloff-Shani.